We report that SEC23A mRNA expression is associated with the overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI) in some cancers such as adrenocortical carcinoma, bladder urothelial carcinoma (BLCA), cervical cancer, kidney renal papillary cell carcinoma, and uveal melanoma. This evidence concerns the gene SEC23A and adrenal cortex carcinoma.